RxDoctor Payments Data

David Adams

Nurse Practitioner · Ammon, IDNPI 1417443631

Payments from drug & device makers

$1,285in general payments, 2019–2025

Across 70 payments — averaging $18.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$233
  • AbbVie$199
  • Otsuka America Pharmaceutical, Inc.$169
  • Teva Pharmaceuticals USA, Inc.$112
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$103
  • Vanda Pharmaceuticals Inc.$76
  • plus $394 from 12 others

What the payments were for

  • Food & beverage$1,285100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,285 in reported general payments places this provider in the 80th percentile of 570 nurse practitioner providers in Idaho.

See all nurse practitioner providers in Idaho

Medicare billing

Part B allowed, 2024
$13,158
Medicare patients
47
Services billed
225

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide84$81,878
Invega SustennaPaliperidone Palmitate18$64,424
RybelsusSemaglutide60$56,462
EliquisApixaban70$37,677
FarxigaDapagliflozin Propanediol58$31,438
LinzessLinaclotide57$29,100
VascepaIcosapent Ethyl80$23,863
Stiolto RespimatTiotropium Br/Olodaterol Hcl40$20,067
RexultiBrexpiprazole14$19,989
ViberziEluxadoline11$18,081
MyrbetriqMirabegron19$10,545
Lurasidone Hcl36$10,380
Fluticasone Propionate HfaFluticasone Propionate29$7,411
MovantikNaloxegol Oxalate16$6,868
TradjentaLinagliptin13$6,603

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$59$64,42418 claims
AbbVieLinzess, Viberzi$199$47,18168 claims
AstraZenecaFarxiga, Bevespi Aerosphere$13$35,88269 claims
Otsuka America Pharmaceutical, Inc.Rexulti$169$19,98914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 570 nurse practitioner providers in Idaho.

Other nurse practitioner in Ammon

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →